Dr Reddy's to launch semaglutide injection in India in March
This story was originally published at 21:25 IST on 21 January 2026
Register to read our real-time news.Informist, Wednesday, Jan. 21, 2026
Please click here to read all liners published on this story
--Dr Reddy's:Q3 base business, excluding Revlimid posted double digit growth
--CONTEXT: Comments from Dr Reddy's mgmt at post Q3 earings press conference
--Dr Reddy's: Got regulatory OK for semaglutide in India, to launch in March
--Dr Reddy's: 85% integration of nicotine therapy portfolio in Europe
-- Dr Reddy's: Saw moderate price erosion in Oct-Dec in North America
--Dr Reddy's: Nicotine therapy portfolio driving Europe sales growth
--Dr Reddy's: Expect to resolve semaglutide regulatory issues in Canada soon
--Dr Reddy's: Semaglutide India launch will be with competitive pricing
--Dr Reddy's: To make semaglutide pdts on own, may supply to some partners
--Dr Reddy's:Enough capacity to meet semaglutide demand in India, other mkts
--Dr Reddy's: Working on inorganic, organic opportunities for US growth
-- Dr Reddy's: Have very good pipeline to drive US future growth
--Dr Reddy's: Working product pipeline for US to replace generic Revlimid
--Dr Reddy's: India semaglutide March launch for only diabetic treatment
--Dr Reddy's: Dedicated team is working on semaglutide India marketing
--Dr Reddy's: Expects to launch semaglutide in 80 countries in next 6 months
--Dr Reddy's: R&D spending will remain 7-8% of total sales going forward
By Narayana Krishna and Eshitva Prakash
MUMBAI – Dr. Reddy's Laboratories Ltd. is gearing up to launch its first glucagon-like peptide-1 category drug generic semaglutide in India in March, the management told a post-earnings press conference Wednesday. The company has already received regulatory clearance from the Drugs Controller General of India and a dedicated team is working to begin marketing the product.
Considering the entry of global pharmaceutical majors Eli Lilly and Co. and Novo Nordisk A/S with their products in the category in India, Dr. Reddy's is adopting a competitive pricing strategy.
Dr. Reddy's Wednesday after market hours reported a consolidated net profit of INR 12.10 billion for the December quarter, down 14.4% on year. The company's net profit fell after four consecutive quarters of growth. The revenue for the quarter was up 4.4% on year at INR 87.53 billion. The revenue growth is the slowest in 21 quarters. However, both net profit and revenue are above the Street's estimates.
The company's management said the much-awaited India launch of semaglutide will be purely for use in diabetes cases for now, in line with current regulatory approval. The drug will be manufactured entirely by the company as it has adequate capacity. However, the company may outsource the fill-and-finish job of the injections to a third party, it said.
Dr. Reddy's said it is also equipped to supply semaglutide to some of its marketing partners across markets on a business-to-business basis. The company expects to launch semaglutide in 80 countries from the date of its India launch. The patent expiry date for semaglutide is Mar. 21.
On the launch in Canada, where the company has got queries from regulator Health Canada, Dr. Reddy's expects an early resolution. Once the authorisation from the regulator is in place, the company will launch the drug in the country, the management said. Dr. Reddy's hopes the Canada launch may be done before May. The company is targeting the sale of 12 million injection pens in one year from the date of its India launch.
Dr. Reddy's expects its US base business to continue to report growth, though it is working on alternative products to mitigate the impact of lower sales of cancer drug generic Revlimid. For the December quarter, Dr. Reddy's reported 12% year-on-year and 9% quarter-on-quarter fall in its North America sales to INR 29.6 billion. The fall in sales is mainly on account of lower sales of Revlimid in the US.
The management said there is a good pipeline of products for the US market, which may help the company to drive future growth. It said the company is considering organic and inorganic opportunities to drive growth in the country. It is also considering in-licensing deals for the US. Dr. Reddy's said there was moderate price erosion in some products in the December quarter, which also affected its US performance.
Dr. Reddy's said 85% of the integration of nicotine replacement therapy products in Europe has been completed. It expects further growth in Europe, helped by this portfolio. In Russia, along with positive traction in existing products, positive foreign exchange momentum helped the company.
Dr. Reddy's said its spending on research and development will remain at 7-8% of total sales going forward. The company has spent nearly $100 million on its biosimilar auto-immune drug Abatacept.
Wednesday, shares of Dr. Reddy's ended 0.8% lower at INR 1,157.20 on the National Stock Exchange. End
US$1 = INR 91.69
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
